SELLAS Life Sciences (SLS) Other Operating Expenses (2011 - 2023)
SELLAS Life Sciences (SLS) reported Other Operating Expenses of $184000.0 for Q1 2023, up 2144.44% year-over-year from $8198.0 in Q1 2022, and up 48.39% on a QoQ basis from $124000.0 in Q3 2022.
SELLAS Life Sciences (SLS) has 13 years of Other Operating Expenses data on file, last reported at $184000.0 in Q1 2023.
- Quarterly Other Operating Expenses rose 2144.44% year-over-year to $184000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $184000.0 (down 43.21% YoY) and the FY2022 annual result came in at $10.1 million, up 71.19% from the prior year.
- Other Operating Expenses rose to $184000.0 in Q1 2023 per SLS's latest filing, from $124000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $5.7 million in Q4 2021 and bottomed at -$178000.0 in Q1 2019.
- The 5-year median for Other Operating Expenses is -$18000.0 (2019), against an average of $415466.7.
- The widest annual swing landed in 2021, when Other Operating Expenses slumped 668.42%; it then surged 2144.44% in 2023.
- Tracing SLS's Other Operating Expenses over 5 years: stood at -$21000.0 in 2019, then surged by 190.48% to $19000.0 in 2020, then soared by 29900.0% to $5.7 million in 2021, then tumbled by 97.82% to $124000.0 in 2022, then jumped by 48.39% to $184000.0 in 2023.
- Per Business Quant, the three latest SLS Other Operating Expenses figures stand at $184000.0 (Q1 2023), $124000.0 (Q3 2022), and $209000.0 (Q2 2022).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 184,000.00 |
| Sep 30, 2022 | 124,000.00 |
| Jun 30, 2022 | 209,000.00 |
| Mar 31, 2022 | -9,000.00 |
| Dec 31, 2021 | 5.70 Mn |
| Sep 30, 2021 | -108,000.00 |
| Jun 30, 2021 | -160,000.00 |
| Mar 31, 2021 | -158,000.00 |
| Sep 30, 2020 | 19,000.00 |
| Jun 30, 2020 | -158,000.00 |
| Mar 31, 2020 | -79,000.00 |
| Dec 31, 2019 | -21,000.00 |
| Sep 30, 2019 | -18,000.00 |
| Jun 30, 2019 | 885,000.00 |
| Mar 31, 2019 | -178,000.00 |
| Dec 31, 2018 | 979,000.00 |
| Sep 30, 2018 | 2.77 Mn |
| Jun 30, 2018 | 602,000.00 |
| Mar 31, 2018 | -2.31 Mn |
| Dec 31, 2017 | -102,000.00 |
| Sep 30, 2017 | -102,000.00 |
| Jun 30, 2017 | -128,000.00 |
| Mar 31, 2017 | -130,000.00 |
| Dec 31, 2016 | 30.19 Mn |
| Jun 30, 2016 | 17.57 Mn |
| Mar 31, 2016 | -4.13 Mn |
| Dec 31, 2015 | -5.28 Mn |
| Mar 31, 2015 | 606,000.00 |
| Dec 31, 2014 | -12.19 Mn |
| Sep 30, 2014 | 7.04 Mn |
| Jun 30, 2014 | -4.16 Mn |
| Mar 31, 2014 | 9.31 Mn |
| Dec 31, 2013 | 6.75 Mn |
| Sep 30, 2013 | -1.24 Mn |
| Dec 31, 2012 | -385,000.00 |
| Jun 30, 2012 | 49,000.00 |
| Dec 31, 2011 | 3.83 Mn |
| Sep 30, 2011 | -4.19 Mn |
| Jun 30, 2011 | -2.04 Mn |